Cue Biopharma, Inc.
CUE
$29.47
$0.210.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.47M | 7.10M | 8.29M | 7.99M | 9.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.47M | 7.10M | 8.29M | 7.99M | 9.29M |
| Cost of Revenue | 49.07M | 46.26M | 46.57M | 48.19M | 49.84M |
| Gross Profit | -21.61M | -39.16M | -38.28M | -40.20M | -40.55M |
| SG&A Expenses | 18.34M | 19.11M | 17.34M | 17.17M | 17.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.99M | 45.21M | 47.76M | 49.21M | 50.88M |
| Operating Income | -26.52M | -38.11M | -39.48M | -41.22M | -41.59M |
| Income Before Tax | -26.10M | -37.68M | -38.90M | -40.58M | -40.67M |
| Income Tax Expenses | 500.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.60 | -37.68 | -38.90 | -40.58 | -40.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.60M | -37.68M | -38.90M | -40.58M | -40.67M |
| EBIT | -26.52M | -38.11M | -39.48M | -41.22M | -41.59M |
| EBITDA | -25.56M | -37.73M | -39.08M | -40.82M | -41.20M |
| EPS Basic | -0.31 | -0.46 | -0.55 | -0.66 | -0.75 |
| Normalized Basic EPS | -0.19 | -0.28 | -0.35 | -0.42 | -0.47 |
| EPS Diluted | -0.31 | -0.46 | -0.55 | -0.66 | -0.75 |
| Normalized Diluted EPS | -0.19 | -0.28 | -0.35 | -0.42 | -0.47 |
| Average Basic Shares Outstanding | 378.57M | 344.82M | 295.18M | 249.90M | 225.11M |
| Average Diluted Shares Outstanding | 381.10M | 344.82M | 295.18M | 249.90M | 225.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |